1.Role of interventional endoscopic ultrasound in a developing country
Hasan MAULAHELA ; Nagita Gianty ANNISA ; Achmad FAUZI ; Kaka RENALDI ; Murdani ABDULLAH ; Marcellus SIMADIBRATA ; Dadang MAKMUN ; Ari Fahrial SYAM
Clinical Endoscopy 2023;56(1):100-106
Background/Aims:
Endoscopic ultrasound (EUS) has become an essential diagnostic and therapeutic tool. EUS was introduced in 2013 in Indonesia and is considered relatively new. This study aimed to describe the current role of interventional EUS at our hospital as a part of the Indonesian tertiary health center experience.
Methods:
This retrospective study included all patients who underwent interventional EUS (n=94) at our center between January 2015 and December 2020. Patient characteristics, technical success, clinical success, and adverse events associated with each type of interventional EUS procedure were evaluated.
Results:
Altogether, 94 interventional EUS procedures were performed at our center between 2015 and 2020 including 75 cases of EUS-guided biliary drainage (EUS-BD), 14 cases of EUS-guided pancreatic fluid drainage, and five cases of EUS-guided celiac plexus neurolysis. The technical and clinical success rates of EUS-BD were 98.6% and 52%, respectively. The technical success rate was 100% for both EUS-guided pancreatic fluid drainage and EUS-guided celiac plexus neurolysis. The adverse event rates were 10.6% and 7.1% for EUS-BD and EUS-guided pancreatic fluid drainage, respectively.
Conclusions
EUS is an effective and safe tool for the treatment of gastrointestinal and biliary diseases. It has a low rate of adverse events, even in developing countries.
2.Development, Translation and Validation of Enhanced Asian Rome III Questionnaires for Diagnosis of Functional Bowel Diseases in Major Asian Languages: A Rome Foundation-Asian Neurogastroenterology and Motility Association Working Team Report.
Uday C GHOSHAL ; Kok Ann GWEE ; Minhu CHEN ; Xiao R GONG ; Nitesh PRATAP ; Xiaohua HOU ; Ari F SYAM ; Murdani ABDULLAH ; Young Tae BAK ; Myung Gyu CHOI ; Sutep GONLACHANVIT ; Andrew S B CHUA ; Kuck Meng CHONG ; Kewin T H SIAH ; Ching Liang LU ; Lishou XIONG ; William E WHITEHEAD
Journal of Neurogastroenterology and Motility 2015;21(1):83-92
BAome III criteria. METHODS: After EAR3Q was developed by Asian experts by cCKGROUND/AIMS: The development-processes by regional socio-cultural adaptation of an Enhanced Asian Rome III questionnaire (EAR3Q), a cultural adaptation of the Rome III diagnostic questionnaire (R3DQ), and its translation-validation in Asian languages are presented. As English is not the first language for most Asians, translation-validation of EAR3Q is essential. Hence, we aimed to culturally adapt the R3DQ to develop EAR3Q and linguistically validate it to show that the EAR3Q is able to allocate diagnosis according to Ronsensus, it was translated into Chinese, Hindi-Telugu, Indonesian, Korean, and Thai, following Rome Foundation guidelines; these were then validated on native subjects (healthy [n = 60], and patients with irritable bowel syndrome [n = 59], functional dyspepsia [n = 53] and functional constipation [n = 61]) diagnosed by clinicians using Rome III criteria, negative alarm features and investigations. RESULTS: Experts noted words for constipation, bloating, fullness and heartburn, posed difficulty. The English back-translated questionnaires demonstrated concordance with the original EAR3Q. Sensitivity and specificity of the questionnaires were high enough to diagnose respective functional gastrointestinal disorders (gold standard: clinical diagnoses) in most except Korean and Indonesian languages. Questionnaires often uncovered overlapping functional gastrointestinal disorders. Test-retest agreement (kappa) values of the translated questionnaires were high (0.700-1.000) except in Korean (0.300-0.500) and Indonesian (0.100-0.400) languages at the initial and 2-week follow-up visit. CONCLUSIONS: Though Chinese, Hindi and Telugu translations were performed well, Korean and Indonesian versions were not. Questionnaires often uncovered overlapping FGIDs, which were quite common.
Asia
;
Asian Continental Ancestry Group*
;
Constipation
;
Diagnosis*
;
Dyspepsia
;
Follow-Up Studies
;
Gastrointestinal Diseases
;
Heartburn
;
Humans
;
Irritable Bowel Syndrome
;
Surveys and Questionnaires*
;
Sensitivity and Specificity
;
Translations
3.Differences in the insulin resistance levels measured by HOMA-IR between patients with erosive and non-erosive gastroesophageal reflux disease
Laras Budiyani ; Dyah Purnamasari ; Marcellus Simadibrata ; Murdani Abdullah
Journal of the ASEAN Federation of Endocrine Societies 2017;32(2):139-144
Background:
Insulin resistance is the core of Metabolic Syndrome which carries a high risk for cardiovascular events. Insulin resistance had been reported to be higher in GERD patients than subjects without GERD, specifically in erosive esophagitis.
Objective:
To compare the degree of insulin resistance, using HOMA-IR index, between erosive and non-erosive reflux disease.
Methodology:
A cross-sectional study of 84 adult patients with GERD symptoms was conducted. The subjects were recruited consecutively between January 2017 and April 2017 at Cipto Mangunkusumo National Hospital in Jakarta. Gastroesophageal Reflux Disease Questionnaire (GERDQ) was used for subject recruitment. Homeostatic model assessment-insulin resistance (HOMA-IR) index was used to evaluate insulin sensitivity. Esophageal erosions were diagnosed using upper gastrointestinal endoscopy. Bivariate analysis was used to determine HOMA-IR difference between esophagitis and non-esophagitis group.
Results:
The median of HOMA-IR in all subjects was 1.46 (0.32-13.85). Mann-Whitney test revealed that HOMA-IR index was higher in patients with erosive esophagitis [median 1.74 (0.35-13.85)] than those without erosive esophagitis [median 1.21 (0.32-10.78)] (p=0.05).
Conclusion
Insulin resistance is significantly higher in gastroesophageal reflux disease patients with esophageal erosions than in those without esophageal erosion.
Insulin Resistance
4.Primary Care Management of Chronic Constipation in Asia: The ANMA Chronic Constipation Tool.
Kok Ann GWEE ; Uday C GHOSHAL ; Sutep GONLACHANVIT ; Andrew Seng Boon CHUA ; Seung Jae MYUNG ; Shaman RAJINDRAJITH ; Tanisa PATCHARATRAKUL ; Myung Gyu CHOI ; Justin C Y WU ; Min Hu CHEN ; Xiao Rong GONG ; Ching Liang LU ; Chien Lin CHEN ; Nitesh PRATAP ; Philip ABRAHAM ; Xiao Hua HOU ; Meiyun KE ; Jane D RICAFORTE-CAMPOS ; Ari Fahrial SYAM ; Murdani ABDULLAH
Journal of Neurogastroenterology and Motility 2013;19(2):149-160
Chronic constipation (CC) may impact on quality of life. There is substantial patient dissatisfaction; possible reasons are failure to recognize underlying constipation, inappropriate dietary advice and inadequate treatment. The aim of these practical guidelines intended for primary care physicians, and which are based on Asian perspectives, is to provide an approach to CC that is relevant to the existing health-care infrastructure. Physicians should not rely on infrequent bowel movements to diagnose CC as many patients have one or more bowel movement a day. More commonly, patients present with hard stool, straining, incomplete feeling, bloating and other dyspeptic symptoms. Physicians should consider CC in these situations and when patients are found to use laxative containing supplements. In the absence of alarm features physicians may start with a 2-4 week therapeutic trial of available pharmacological agents including osmotic, stimulant and enterokinetic agents. Where safe to do so, physicians should consider regular (as opposed to on demand dosing), combination treatment and continuous treatment for at least 4 weeks. If patients do not achieve satisfactory response, they should be referred to tertiary centers for physiological evaluation of colonic transit and pelvic floor function. Surgical referral is a last resort, which should be considered only after a thorough physiological and psychological evaluation.
Asia
;
Asian Continental Ancestry Group
;
Colon
;
Constipation
;
Health Resorts
;
Humans
;
Pelvic Floor
;
Physicians, Primary Care
;
Primary Health Care
;
Quality of Life
;
Referral and Consultation
;
Sprains and Strains
5.Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
Choon Jin OOI ; Ida HILMI ; Rupa BANERJEE ; Sai Wei CHUAH ; Siew Chien NG ; Shu Chen WEI ; Govind K MAKHARIA ; Pises PISESPONGSA ; Min Hu CHEN ; Zhi Hua RAN ; Byong Duk YE ; Dong Il PARK ; Khoon Lin LING ; David ONG ; Vineet AHUJA ; Khean Lee GOH ; Jose SOLLANO ; Wee Chian LIM ; Wai Keung LEUNG ; Raja Affendi Raja ALI ; Deng Chyang WU ; Evan ONG ; Nazri MUSTAFFA ; Julajak LIMSRIVILAI ; Tadakazu HISAMATSU ; Suk Kyun YANG ; Qin OUYANG ; Richard GEARY ; Janaka H DE SILVA ; Rungsun RERKNIMITR ; Marcellus SIMADIBRATA ; Murdani ABDULLAH ; Rupert WL LEONG ;
Intestinal Research 2019;17(3):285-310
The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in the conjunction with conventional treatments for ulcerative colitis (UC) and Crohn's disease (CD) in Asia. These statements also address how pharmacogenetics influence the treatments of UC and CD and provide guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of IBD workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing and future revisions are likely as new data continue to emerge.
Adalimumab
;
Asia
;
Asian Continental Ancestry Group
;
Biological Factors
;
Biosimilar Pharmaceuticals
;
Colitis
;
Colitis, Ulcerative
;
Consensus
;
Cooperative Behavior
;
Crohn Disease
;
Gastroenterology
;
Hepatitis B
;
Humans
;
Immunologic Factors
;
Inflammatory Bowel Diseases
;
Infliximab
;
Pharmacogenetics
;
Philippines
;
Practice Guidelines as Topic
;
Tuberculosis
;
Ulcer